Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Slides:

Advertisements

Similar presentations

Pascal Rischmann European Urology Supplements

Advertisements

2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections Rodolfo Montironi,

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Shock Wave Lithotripsy for Renal and Ureteric Stones

Hormone Therapy for Prostate Cancer: Exploring Current Controversies

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Shock Wave Lithotripsy for Renal and Ureteric Stones

Martin C. Michel European Urology Supplements

What is New in Bladder Cancer Diagnosis and Management?

Back to the Future: Introduction and Conclusions

Volume 51, Issue 1, Pages (January 2007)

What is New in Hormone Therapy for Prostate Cancer in 2007?

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Advances in the Therapy of Prostate Cancer–Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL Pathways Kurt Miller, Arnulf.

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

An Update of Current Practice in Hypospadias Surgery

Richard C. Harkaway European Urology Supplements

RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer Matthew R. Smith European Urology Supplements

Volume 50, Issue 5, Pages (November 2006)

Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma Sergio Bracarda, Alain Ravaud, Marino.

The Importance of Testosterone Control in Prostate Cancer

Antonio Alcaraz, Pierre Teillac European Urology Supplements

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

Volume 26, Issue 2, Pages (February 2018)

Jacques Irani European Urology Supplements

Optimal Testosterone Control and Eligard®

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Neal Shore European Urology Supplements

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

Bladder Cancer: Highlights from 2006

Sergio Bracarda European Urology Supplements

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Christian Stief European Urology Supplements

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Who Forms Stones and Why?

Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer P. Mongiat-Artus, P. Teillac

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Richard Berges European Urology Supplements

Axel Heidenreich European Urology Supplements

Improving Flexibility and Quality of Life for Your Patients: A Must?

Profile of Silodosin European Urology Supplements

Stone Disease European Urology Supplements

New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men

Highlighting Unmet Needs: Real Patients, Difficult Choices

Epidemiology, Pathogenesis, and Pathophysiology of Urolithiasis

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Testim® Gel: Review of Clinical Data

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Counselling of the Prostate Cancer Patient as a Whole Person

Bertrand Tombal, Richard Berges

Joaquim Bellmunt European Urology Supplements

Hormone Therapy: Improving Therapy Decisions and Monitoring

The Impact of Premature Ejaculation on Partners and Relationships

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Diagnosis and Management of Cryptorchidism

Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Jan Roigas European Urology Supplements

Axel Heidenreich European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

Michael Marberger European Urology Supplements

Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone? B. Tombal European Urology.

Presentation transcript:

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology Supplements Volume 7, Issue 1, Pages 15-21 (February 2008) DOI: 10.1016/j.eursup.2007.11.001 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Voting results on the question: “Which of these indications is not an evidence-based recognised indication of androgen-deprivation therapy?” European Urology Supplements 2008 7, 15-21DOI: (10.1016/j.eursup.2007.11.001) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Voting results on the question: “If available, would the patient prefer a 6-mo depot formula to increase the interval between two injections?” European Urology Supplements 2008 7, 15-21DOI: (10.1016/j.eursup.2007.11.001) Copyright © 2007 European Association of Urology Terms and Conditions